A31G
Category 5 — IDR ExclusionConflictingCytoplasmic · predictedEditorialAlanine → Glycine at position 31 in wolframin's N-terminal intrinsically disordered region (IDR). ClinVar carries conflicting classifications. AlphaMissense 0.100 (likely BENIGN). pLDDT 28 — deep IDR. DynaMut2 ΔΔG -0.35 kcal/mol but NOT trustworthy. A Category 5 IDR variant flagged for wet-lab validation.
Interactive 3D Structure
Computational Predictions
Clinical Evidence
Observed at very low frequency in gnomAD.
Structural Context
Position 31 sits in wolframin's N-terminal IDR. The pLDDT score of 28 indicates that AlphaFold cannot reliably predict the local conformation — the protein adopts an ensemble of structures in this region rather than a single fold. Neighbor analysis returns only the immediate sequence neighbors (SER32 at 2.5 Å, THR30 at 2.6 Å, LEU33 at 4.6 Å) — the structural signature of IDR.
Replacing alanine with glycine adds backbone flexibility. Glycine permits backbone conformations (especially in the Ramachandran left-handed helix region) that other amino acids cannot adopt. In a folded protein this is sometimes structurally significant. In an IDR, where the protein is already conformationally heterogeneous, the impact is more subtle — the ensemble's accessible conformational space shifts slightly, but no single 'wild-type' geometry is being broken.
DynaMut2's |ΔΔG| of 0.35 kcal/mol is not interpretable as a quantitative claim in this region. AlphaMissense's 0.100 score (well below the 0.564 pathogenic threshold) considers the variant likely benign.
The conflicting ClinVar classifications — some pathogenic, some uncertain — likely reflect that this variant has been observed in patients with Wolfram-spectrum disease but causal contribution has not been firmly established. The mechanism, if pathogenic, would likely involve IDR-mediated phase separation, partner binding through disordered regions, or context-dependent functional disruption — none of which AlphaMissense's training reliably captures.
Druggability Assessment
The Atlas routes Category 5 variants to wet-lab characterization rather than computational drug discovery. For A31G specifically, the recommended next steps are: (1) verify the clinical association with case-by-case review; (2) characterize the IDR's functional role; (3) test the variant in functional assays. Therapeutic strategy decisions should not be made on the current computational data alone.
Why this matters
Feed this card to Wolfram Intelligence
Download the A31G PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.